摘要
目的观察乳腺癌分子分型对乳腺癌患者保乳手术预后的影响。方法回顾性分析天津医科大学肿瘤医院1999年1月至2007年12月期间收治的699例行保乳手术的乳腺癌患者的临床资料。按术后免疫组化结果将患者分为4组:LuminalA[雌激素受体(ER)+/孕激素受体(PR)+/表皮生长因子受体(HER)2-,Ki-67〈14%)],LuminalB(ER+/PR+/HER2±,Ki-67〉14%),HER2(ER-/PR-/HER2+)和三阴性(ER-/PR-/HER2-)。根据不同分组,比较其生存率、复发及转移等预后影响因素。结果699例保乳患者中,其中局部复发患者42例,5年复发率6.0%,远处转移42例,占6.0%,乳腺癌5年生存率91.8%。多因素结果显示不同分子分型(P〈0.001),淋巴结状态(P〈0.001)及是否进行化疗(P〈0.001)的患者的乳腺癌生存率和远处转移率差异有统计学意义。虽然单因素分析显示不同分子分型乳腺癌患者保乳术乳后局部复发存在差异(P=0.022),但多因素结果显示分子分型并不是局部复发的独立预后因素(P=0.081)。结论虽然与其他类型乳腺癌患者相比,三阴性患者的预后较差,但是保乳治疗仍然是该类患者可行的治疗选择。
Objective To evaluate the effects of molecular subtypes on the prognosis of breast cancer patients after BCT (breast-conserving therapy). Methods From January 1999 to December 2007, a total of 699 female patients on BCT were analyzed retrospectively. They were grouped according to the results of immunohistochemistry, they were grouped as Luminal A (ER +/PR +/HER2-, Ki-67 〈 14% ), Luminal B (ER +/PR +/HER2 ±, Ki-67 〉 14% ), HER2 (ER -/PR -/HER2 + ) and triple negative breast cancer ( TNBC ) ( ER -/PR -/HER2 - ). Results Among them, the recurrence rate, metastasis rate and survival rate within 5 years after BCT accounted for 6. 0%, 6. 0% and 91.8% respectively. There were statistical differences in metastasis rate and survival rate among patients with different molecular subtypes (P 〈 0. 001 ), lymph node status(P 〈0. 001 )and on chemotherapy or not (P 〈0. 001 )on multivariate analysis. Though, on univariate analysis, different molecular subtypes had different risks for local failure (P = 0. 022 ) . On multivariate analysis, this difference was not statistically significant (P = 0. 081 ). Conclusion Despite a worse prognosis of TNBC versus other subtypes, BCT is a viable option for selected TNBC patients.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第20期1571-1573,共3页
National Medical Journal of China
关键词
乳腺肿瘤
受体
预后
Breast neoplasms
Receptor
Prognosis